Sting-associated vasculopathy with onset in infancy is a rare genetic condition that causes ongoing inflammation in many parts of the body. Many people with Sting-associated vasculopathy with onset in infancy develop early skin changes such as a persistent rash, swelling of fingers or toes, and sensitivity to cold, and doctors may also see small vessel inflammation. Lung problems can develop over time, and some children have growth delays or joint pain. The condition is lifelong, and severity varies, but serious complications can occur without treatment. Care usually includes anti-inflammatory medicines, and newer targeted treatments that calm the immune pathway can help many people with Sting-associated vasculopathy with onset in infancy.
Overview
Sting-associated vasculopathy with onset in infancySymptoms
Sting-associated vasculopathy with onset in infancy (SAVI) causes recurring fevers, cough and fast breathing from lung inflammation, and painful, cold-triggered skin sores on fingers, toes, and nose. Many children also have poor weight gain. Joints may become stiff.
Outlook and prognosis
Most children with STING-associated vasculopathy with onset in infancy (SAVI) face ongoing inflammation that can affect lungs, skin, and growth, but severity varies widely. Earlier diagnosis and targeted treatments can ease flares, protect lung function, and improve day-to-day comfort. Regular monitoring helps tailor care as needs change.
Causes and risk factors
SAVI (Sting-associated vasculopathy with onset in infancy) is caused by overactivating changes in the TMEM173/STING gene, often autosomal dominant. Many cases are new mutations. Having an affected parent raises risk; cold, infections, and pollutants can worsen symptoms without causing SAVI.
Genetic influences
Genetics is central to STING‑associated vasculopathy with onset in infancy (SAVI). Pathogenic changes in the TMEM173 gene drive the overactive STING pathway, causing inflammation. SAVI is typically inherited in an autosomal dominant pattern, though many cases arise from new (de novo) variants.
Diagnosis
Doctors suspect Sting-associated vasculopathy with onset in infancy from early, recurrent inflammation affecting skin and lungs. They assess labs and imaging, sometimes biopsy. Genetic diagnosis of Sting-associated vasculopathy with onset in infancy is confirmed by TMEM173 testing.
Treatment and drugs
Treatment for Sting-associated vasculopathy with onset in infancy focuses on calming the overactive immune signaling and protecting skin, lungs, and growth. Doctors often use JAK inhibitors (like ruxolitinib or baricitinib), plus tailored skin care, infection prevention, and supportive therapies. Regular monitoring guides dose adjustments and addresses complications early.
Symptoms
Many families first notice fussiness, fevers, and skin changes on little fingers and toes within the first months of life. These early features of Sting-associated vasculopathy with onset in infancy often involve cold‑sensitive sores and breathing issues that make feeding or sleep harder. Features vary from person to person and can change over time. Cold weather or even a short time outside can make the skin symptoms flare.
Frequent or prolonged fevers, often above 38°C (100.4°F), can show up without an obvious infection. Babies may be irritable, sleep poorly, or feed less during flares. Fevers are a frequent sign in Sting-associated vasculopathy with onset in infancy.
Red-purple patches and open sores on fingers, toes, ears, or the nose are common. Cold or wind can make the areas sting or throb, and small injuries may take a long time to heal. In Sting-associated vasculopathy with onset in infancy, these sores reflect inflamed small blood vessels under the skin.
Fingers and toes may turn pale, blue, or red with cold exposure, then tingle or ache as blood flow returns. Over time, the skin at the tips can break down, leading to cracks or small ulcers.
A dry cough, fast breathing, or getting winded with light activity can develop. In medical terms, this is interstitial lung disease; in everyday life, it shows up as limits on play, feeding, or sleep. The lungs are commonly affected in Sting-associated vasculopathy with onset in infancy.
How people usually first notice Sting-associated vasculopathy with onset in infancy?
Many families first notice something is wrong in the first weeks to months of life: a baby with persistent fevers, irritability, poor weight gain, and unusual skin changes—often painful red or purple patches or sores on fingers, toes, ears, or nose that can ulcerate, especially with cold exposure. Doctors are alerted by ongoing inflammation without clear infection, early-onset chilblain-like lesions, and breathing concerns such as rapid breathing or cough; imaging or tests may show lung inflammation and scarring, and labs often reveal high inflammatory markers, pointing to the first signs of Sting-associated vasculopathy with onset in infancy (SAVI). Genetic testing typically confirms the diagnosis after these early clues raise concern for an autoinflammatory condition.
Types of Sting-associated vasculopathy with onset in infancy
Sting-associated vasculopathy with onset in infancy (SAVI) is a rare genetic autoinflammatory disease caused by gain‑of‑function changes in the STING1 gene. There are no universally accepted “types of SAVI” the way some conditions have fixed subtypes, but doctors do recognize clinical variants tied to different STING1 mutations and organ patterns. People with SAVI often share core features like skin inflammation and lung disease, yet severity and organ involvement can vary meaningfully from one variant to another. Not everyone will experience every type.
V147 variants
These changes are linked to early, severe skin inflammation and vessel damage, often starting on cheeks, nose, ears, fingers, and toes. Lung involvement can appear early and may progress despite treatment. Children may have growth impact due to chronic inflammation.
N154 variants
These variants can present with prominent lung disease, including early interstitial changes and scarring. Skin findings still occur but may be milder or appear later compared with other variants. Fatigue and poor weight gain can track with lung severity.
V155 variants
People may have both marked skin vasculopathy and significant lung disease, with flares triggered by infections or cold. Digital ulcers, tissue loss at fingertips, and nasal tip changes can develop over time. Joint aches and low‑grade fevers may cluster with flares.
C206 variants
These are associated with pronounced blood‑vessel–driven skin changes and sensitivity to cold, sometimes with less severe lung disease than other variants. Recurrent chilblain‑like lesions and color changes in fingers and toes are common. Growth and energy levels often reflect the overall inflammatory burden.
R281 variants
Some families show a mix of skin inflammation and variable lung involvement, with symptoms ranging from mild to severe. Mouth ulcers and ear or nose lesions can be early clues in children. Doctors sometimes classify symptoms as cutaneous‑predominant versus pulmonary‑predominant.
Pulmonary‑predominant
Lung symptoms lead—shortness of breath with exertion, dry cough, and fatigue—with skin findings less obvious or delayed. Imaging may show early interstitial lung disease or scarring. Clubbing and exercise intolerance can develop if inflammation persists.
Cutaneous‑predominant
Skin and vessel inflammation are most noticeable, with painful red‑purple patches, chilblains, and fingertip ulcers, while lungs are minimally involved at first. Cold weather can trigger flares in hands, feet, ears, and nose. Scarring at the nasal tip or digits may appear over time.
Immune‑dysregulation variant
Some have fewer skin ulcers but more issues with infections, anemia, or low lymphocyte counts due to immune imbalance. Respiratory infections can unmask underlying lung inflammation. Monitoring labs and vaccines becomes central to day‑to‑day care.
What genetics can tell you about symptoms
Some people with STING-associated vasculopathy (SAVI) have variants in the TMEM173 (STING1) gene that “switch on” inflammation early, causing recurrent fevers, rash, mouth sores, and poor weight gain. Certain variants more strongly target the lungs and blood vessels, leading to cough, breathing trouble, and skin ulcers.
Causes and risk factors
STING-associated vasculopathy with onset in infancy is caused by a change in the TMEM173 gene that makes the STING immune pathway overactive. The gene change may be inherited from a parent or may appear for the first time in the child. Some risks are modifiable (things you can change), others are non-modifiable (things you can’t). Family history is a non-modifiable risk for this condition. Environmental risk factors for STING-associated vasculopathy with onset in infancy include cold or viral triggers, tobacco smoke, and air pollution, and avoiding smoke may help reduce flares.
Environmental and biological risk factors
Sting-associated vasculopathy with onset in infancy is a rare condition that typically begins very early in life. Doctors often group risks into internal (biological) and external (environmental). For this condition, environmental and biological risk factors for Sting-associated vasculopathy with onset in infancy mostly relate to the chance of a brand-new change arising before conception rather than anything during pregnancy or after birth. Evidence is limited, but a few well-studied factors can slightly increase the chance of new changes in reproductive cells.
As paternal age increases, the number of brand-new DNA changes that can arise in sperm goes up. This makes a spontaneous change in the baby more likely. The increase is small per year but accumulates over time.
Maternal age also contributes to a smaller rise in new changes that can appear in eggs. This can modestly add to the baseline chance of a spontaneous change in the child.
High-dose ionizing radiation to either parent before conception can damage reproductive cells. This may slightly raise the chance of a new change being passed to the child. Typical background radiation and standard diagnostic imaging use much lower doses.
Long-term exposure to potent DNA-damaging agents such as certain heavy metals or industrial solvents can injure sperm or egg cells. This could increase the odds of new changes arising before conception. Regulations and workplace protections reduce these exposures in most settings.
Genetic risk factors
Sting-associated vasculopathy with onset in infancy (SAVI) stems from inherited or new changes in a single gene that overshoots the body’s immune alarm. The main genetic causes of Sting-associated vasculopathy with onset in infancy are changes in the STING1 gene (also called TMEM173) that make it overactive. These changes can run in families or appear for the first time in a child with no family history. People with the same risk factor can have very different experiences.
STING1 gene changes: Changes in the STING1 gene (also called TMEM173) keep the STING protein switched on. This constant signal drives widespread inflammation typical of SAVI.
Dominant inheritance: Having one altered copy is enough to cause SAVI. An affected parent has a 50% chance to pass the change to each child.
New variants: Many people develop the STING1 change for the first time, with no prior family history. These new (de novo) variants arise in the egg or sperm, or very early after conception.
Parental mosaicism: Occasionally a parent carries the change in only some egg or sperm cells. Routine blood testing can miss this, so a second child could still be at risk.
Child mosaicism: When only some of a child’s cells carry the change, symptoms may start later or be milder. This mosaic pattern can also make genetic test results harder to interpret.
Variant differences: Different STING1 changes can tilt the condition toward more lung or more skin involvement. Early symptoms of Sting-associated vasculopathy with onset in infancy may differ by variant. Knowing the exact change can help guide monitoring.
Family history: Having a parent with a confirmed STING1 change strongly increases risk. Relatives in these families can consider targeted testing to clarify who carries the change.
Lifestyle risk factors
Sting-associated vasculopathy with onset in infancy is a genetic interferonopathy; lifestyle habits do not cause it, but daily choices can influence symptoms, ulcers, lung function, and overall resilience. Understanding how lifestyle affects Sting-associated vasculopathy with onset in infancy can help reduce flares, support wound healing, and improve energy and participation in activities. The elements below focus on practical habits that can modify symptom burden and complications.
Gentle, regular movement and pulmonary-rehab–style exercise can improve breathing efficiency and reduce deconditioning from lung involvement. Overexertion can worsen breathlessness and fatigue, so pacing and rest breaks are important.
Minimizing friction and pressure on fingers, toes, and ulcer-prone areas can reduce skin breakdown and the risk of painful sores. Protective gloves, cushioned socks, and careful wound care support healing.
Tobacco or nicotine exposure worsens vasculopathy and accelerates lung damage in SAVI. Avoiding smoking and secondhand smoke helps preserve lung function and circulation.
Adequate protein, calories, and micronutrients (like vitamin C, zinc, and iron) support growth and skin ulcer healing in SAVI. Anti-inflammatory eating patterns rich in fruits, vegetables, whole grains, and omega-3s may help symptom control.
Risk prevention
You can’t prevent Sting-associated vasculopathy with onset in infancy (SAVI) itself, but you can lower the chance of flares and complications that affect skin, lungs, and growth. Prevention is about lowering risk, not eliminating it completely. Day to day, that means protecting from triggers, staying up to date with care, and acting early when something changes. Work with your care team to personalize steps that fit your child’s age, health, and climate.
Learn the early symptoms of Sting-associated vasculopathy with onset in infancy, like new fingertip sores, cold-red painful digits, worsening cough, or fast breathing. Report changes quickly so treatment can start early.
Keep hands, feet, and face warm with layers, mittens, and thermal socks, even indoors if drafty. Avoid direct cold exposure, ice packs on skin, and sudden temperature swings.
Keep routine vaccines current as advised by your specialist, and ask which vaccines are recommended or should be timed carefully. Practice handwashing and seek prompt care for fevers or breathing changes.
Give prescribed immune-targeting medicines on schedule and do not stop suddenly unless your doctor says to. Track side effects and bring the list to visits so doses can be adjusted safely.
Transmission
Sting-associated vasculopathy with onset in infancy (SAVI) is not contagious—you can’t catch it from someone else through touch, coughing, or everyday contact. The genetic transmission of Sting-associated vasculopathy with onset in infancy is autosomal dominant: if a parent has SAVI, each child has about a 50% chance of inheriting the gene change.
However, many children with SAVI are the first in their family because the change happens for the first time in the egg or sperm and isn’t present in either parent. If you want help understanding how SAVI is inherited and your family’s chances in future pregnancies, a genetics professional can provide personalized guidance.
When to test your genes
Consider genetic testing if a child shows early, recurring fevers, skin rashes, swollen fingers or toes, and breathing issues suggestive of inflammatory lung disease, especially with a family history. Test sooner when symptoms start in infancy or don’t match common autoinflammatory conditions. A confirmed STING mutation guides targeted care and family planning.
Diagnosis
Diagnosis of Sting-associated vasculopathy with onset in infancy (SAVI) often starts with noticing hallmark features—early skin changes on fingers and toes and breathing problems in a very young child—and then confirming the cause with specific tests. Doctors aim for a genetic diagnosis of Sting-associated vasculopathy with onset in infancy by combining clinical clues with targeted testing. Getting a diagnosis is often a turning point toward answers and support. Because SAVI overlaps with other inflammatory and autoimmune conditions, teams usually gather information from several angles to make the diagnosis clear.
Providers look for early-onset skin ulcers, color changes or sores on fingers and toes, and breathing difficulties in infancy or early childhood. They also note fevers, poor weight gain, and flares triggered by cold exposure.
A blood test checks for a disease-causing change in a single gene called TMEM173. Finding this change confirms the diagnosis and can guide care for the child and family.
Specialized blood tests measure activity of interferon-stimulated genes, which is often elevated in SAVI. This pattern supports the diagnosis and can help distinguish SAVI from other types of vasculitis.
A small sample from an active lesion is examined under a microscope. Findings often show inflammation in small blood vessels and help rule out infection or other causes of skin injury.
Stages of Sting-associated vasculopathy with onset in infancy
Sting-associated vasculopathy with onset in infancy does not have defined progression stages. The course can vary widely: some children have frequent inflammatory flares and early lung involvement, while others have stretches of stability, so care teams watch changes over time rather than assign stages. Diagnosis usually pulls together the story of symptoms (including early symptoms of Sting-associated vasculopathy with onset in infancy like persistent fevers, skin color changes or sores, and breathing difficulties), exam findings, blood tests for inflammation, and imaging or lung function checks; genetic testing may be offered to clarify certain risks.
Outlook and prognosis
Living with Sting-associated vasculopathy with onset in infancy (SAVI) can affect growth, energy, skin, lungs, and day-to-day stamina, and these issues often begin very early in life. The outlook is not the same for everyone, but some children have mostly skin and blood-vessel inflammation, while others develop significant lung disease that needs close monitoring. Lung involvement is the main driver of long-term health risks in SAVI; scarring in the lungs (fibrosis) can limit breathing over time, and flare-ups of inflammation may speed that process.
Looking at the long-term picture can be helpful. With current care—targeted anti-inflammatory medicines such as JAK inhibitors, careful infection prevention, and supportive therapies—many people with SAVI have steadier disease control than in the past. Early symptoms of Sting-associated vasculopathy with onset in infancy, like persistent rashes, fingertip sores, or breathing trouble with feeds or activity, deserve prompt attention because early treatment can protect lungs and circulation.
Prognosis refers to how a condition tends to change or stabilize over time. For SAVI, children who respond well to medication and have limited lung scarring often grow and attend school with accommodations, though they may tire faster or need oxygen with exertion. When lung disease is severe or progresses despite treatment, oxygen support and, in rare cases, lung transplant may be considered; serious infections and pulmonary complications are the main reasons for hospitalization and can affect survival. Published reports are still small, but outcomes appear to be improving as diagnosis happens earlier and more children access targeted therapy.
Everyone’s journey looks a little different. Regular follow-up with rheumatology, pulmonology, and dermatology helps catch changes early, and nutrition, vaccines, and hand–foot care can reduce complications. Talk with your doctor about what your personal outlook might look like, including how your child’s specific symptoms, lung function tests, and treatment response shape longer-term expectations. Genetic testing can sometimes provide more insight into prognosis, but not everyone with the same gene change will have the same outlook.
Long-term effects
Living day to day with STING-associated vasculopathy with onset in infancy (SAVI) can mean dealing with changes that build over years, especially in the lungs and skin. Long-term effects vary widely, and doctors may track these changes over years to see how they evolve. Over time, early symptoms of Sting-associated vasculopathy with onset in infancy—like cold-sensitive rashes and poor weight gain—may give way to chronic lung scarring or stubborn skin ulcers. Some reach adulthood with stable health, while others develop breathing problems that limit activity.
Many develop interstitial lung disease that slowly scars lung tissue. This can lead to shortness of breath first with exertion, then sometimes at rest. In some, oxygen support or transplant evaluation is considered.
Lung damage can raise pressure in the blood vessels of the lungs. This strain may cause fatigue, chest discomfort, or swelling in the legs and ankles.
Recurrent inflamed rashes can evolve into painful sores on fingers, toes, ears, face, or legs. These ulcers may heal slowly and leave scars that change skin color or texture.
Reduced blood flow may cause fingertip or toe damage over time. In severe cases, small areas can die back, occasionally leading to partial loss.
How is it to live with Sting-associated vasculopathy with onset in infancy?
Living with STING-associated vasculopathy with onset in infancy (SAVI) often means navigating flare‑ups of inflammation that can affect the skin, lungs, and energy levels, with clinic visits, medicines to calm the immune system, and careful monitoring becoming part of routine life. For many families, day‑to‑day plans may shift around oxygen needs, wound care for skin lesions, avoiding cold exposure that can trigger symptoms, and staying on top of infections. Children can still learn, play, and grow, but they may tire more easily or miss activities during flares, and parents, siblings, and caregivers often take on added roles—coordinating care, watching for early signs of trouble, and offering steady encouragement. With a supportive team, clear treatment goals, and flexible school and social plans, many find a workable rhythm that balances health needs with a full family life.
Treatment and drugs
Treatment for Sting-associated vasculopathy with onset in infancy (SAVI) focuses on calming the overactive immune system, easing symptoms, and preventing organ damage, especially in the lungs and skin. Doctors often use medicines that block specific immune signals, such as JAK inhibitors (for example, ruxolitinib or baricitinib), and may add corticosteroids for short periods to control flares while longer-term treatments take effect. Some people with SAVI also receive supportive care like oxygen, antibiotics for infections, physical therapy, and careful skin and wound care; regular monitoring of lung function and imaging helps track how treatment is working. Because responses vary, a doctor may adjust your dose to balance benefits and side effects, and switch drugs if inflammation or lung disease continues. Ask your doctor about the best starting point for you, including vaccines, infection-prevention steps, and whether clinical trials of newer targeted therapies could be a good fit.
Non-drug treatment
Living with Sting-associated vasculopathy with onset in infancy (SAVI) often means caring for skin, lungs, comfort, and daily routines in practical ways. Alongside medicines, non-drug therapies can help protect fingers and toes, support breathing, and maintain growth and activity. Some steps also help you spot early symptoms of SAVI, like a new cough, faster breathing, or color changes in the fingertips, so you can seek care quickly. Plans are tailored by age and severity, and usually blend home strategies with specialist support.
Keep the whole body warm to help prevent color changes, pain, and skin breakdown in fingers and toes. Use layered clothing, warm gloves and socks, and avoid cold rooms or outdoor exposure when possible. Warm the car and rinse hands in lukewarm (not hot) water after being outside.
Clean ulcers gently, keep them covered with non‑stick dressings, and protect the edges of the skin. A wound‑care nurse can guide dressing choices and off‑loading to reduce pressure. Watch for redness, swelling, or drainage that could signal infection.
Daily use of bland emollients can reduce cracking and help the skin act as a barrier. Apply after bathing and before going out in the cold. Avoid fragranced products that may irritate delicate skin.
Use padded socks, roomy shoes, and cushioned insoles to reduce rubbing on tender areas. Finger and toe guards or silicone sleeves can protect spots that are slow to heal. Check feet and hands each evening for new sore spots.
Your genes may have an impact on how drugs work for you
Medicines for Sting-associated vasculopathy with onset in infancy can work very differently depending on variants in genes that affect drug targets, immune signaling, and how the body processes medicines. Genetic testing may guide dose, predict side effects, and help choose alternatives.
Pharmacological treatments
Medicines for STING‑associated vasculopathy with onset in infancy (SAVI) aim to calm the overactive immune pathway driving skin damage and lung inflammation. Even when early symptoms of SAVI are mostly skin ulcers or breathing trouble, drug therapy is focused on dialing down the root immune signal. First-line medications are those doctors usually try first, based on how well they work and their safety profile.
Ruxolitinib, baricitinib, or tofacitinib can reduce the interferon‑driven inflammation central to SAVI. Many people see fewer skin ulcers and steadier lung function over months. Dosing may be increased or lowered gradually to balance benefit and side effects.
Prednisone or methylprednisolone may calm flares quickly but often don’t control SAVI long term. Doctors usually aim for the lowest effective dose and taper to limit risks like infections, weight gain, and high blood pressure.
Tocilizumab can help some with persistent inflammation when JAK inhibitors alone are not enough. Responses vary, and regular lab checks are needed to watch infection risk and liver tests.
Nifedipine, amlodipine, or sildenafil may improve blood flow to fingers and toes in SAVI, easing pain and helping ulcers heal. These drugs don’t treat the root cause but can reduce tissue damage from poor circulation.
Genetic influences
In most people, Sting-associated vasculopathy with onset in infancy (SAVI) is caused by a change in a single gene called TMEM173, which keeps part of the immune system’s alarm switched on all the time. Family history is one of the strongest clues to a genetic influence. SAVI usually follows a dominant inheritance pattern, meaning one changed copy of the gene is enough to cause the condition; if a parent has the change, each child has a 50% chance of inheriting it. At the same time, many cases happen for the first time in a child because the gene change arises spontaneously, so there may be no prior family history. Symptoms and severity can vary a lot, even among relatives who share the same TMEM173 change. Genetic testing can confirm the diagnosis and pinpoint the specific change, which helps guide care, family planning, and conversations about whether SAVI is inherited.
Is Sting-associated vasculopathy with onset in infancy genetic?
Genetics is central to STING‑associated vasculopathy with onset in infancy (SAVI). Pathogenic changes in the TMEM173 gene drive the overactive STING pathway, causing inflammation. SAVI is typically inherited in an autosomal dominant pattern, though many cases arise from new (de novo) variants.
Pharmacogenetics—how genetics influence drug effects
Because Sting-associated vasculopathy with onset in infancy (SAVI) is driven by changes in the STING gene (TMEM173), treatment often aims to quiet the type I interferon signals those changes switch on. Alongside medical history and lab findings, genetic testing helps confirm SAVI and point to medicines like Janus kinase (JAK) inhibitors that block this pathway. For most people, there isn’t a proven pharmacogenetic test that dictates which JAK inhibitor to use or the exact dose; clinicians adjust dosing based mainly on age, kidney and liver function, and other medications. For example, baricitinib is removed mostly by the kidneys, while ruxolitinib and tofacitinib are processed in the liver, so doctors watch organ function and potential drug interactions closely. The genetic diagnosis still shapes care by steering treatment toward interferon‑blocking strategies and away from options that often help less in SAVI when used alone, like long‑term steroids or nonspecific immune suppressants. Although early symptoms of Sting-associated vasculopathy with onset in infancy often lead to the initial diagnosis, it’s the specific change in TMEM173 that guides targeted therapy and follow‑up.
Interactions with other conditions
Living day to day with STING-associated vasculopathy with onset in infancy (SAVI) can be more complicated when other illnesses are in the picture, especially infections. Colds, flu, RSV, or pneumonia can set off stronger flares of skin sores or breathing trouble, and this risk can be higher if someone is taking medicines that lower immune activity, such as JAK inhibitors or steroids. A condition may “exacerbate” (make worse) symptoms of another, so chronic lung problems from SAVI can also make even routine respiratory infections feel more severe. Because these treatments can slightly raise the chance of serious infections, doctors often screen for tuberculosis and hepatitis before starting them, and they generally avoid live vaccines while the immune system is suppressed; inactivated vaccines are usually preferred. Interferon-based therapies used for other conditions can worsen SAVI, so care teams typically choose different options. Some features can overlap with other immune conditions—like chilblain lupus or other types of vasculitis—which is one reason early symptoms of STING-associated vasculopathy with onset in infancy are sometimes misread at first. Talk with your doctor about how your conditions may influence each other, including whether any medication for one problem could affect treatment choices for another.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described infants with persistent fevers, rashes, and red, irritated eyes that didn’t match common infections. Families sometimes recalled a baby who cried from light sensitivity, or a toddler whose skin looked sunburned on windy days, long before anyone had a name for it. Caregivers in the past focused on comfort—cool cloths, shade, and rest—because treatments were limited and the cause was unclear.
First described in the medical literature as a severe, early-onset inflammatory syndrome, Sting-associated vasculopathy with onset in infancy was initially pieced together from case reports of babies with recurring fevers, rash, and small-vessel inflammation seen on biopsy. Over time, descriptions became more precise as doctors noticed shared features: a lace-like or hive-like rash that worsened with cold or stress, mouth sores, and eye irritation that resembled conjunctivitis. Some children developed growth concerns or signs of lung involvement, clues that the inflammation could touch several organs.
In recent decades, knowledge has built on a long tradition of observation. Clinicians began to recognize a pattern starting in the first weeks or months of life, with flares that came and went. What felt like scattered stories from different clinics started to connect. Not every early description was complete, yet together they built the foundation of today’s knowledge.
Advances in genetics provided a turning point. Researchers identified changes in a gene that acts like a dimmer switch for a pathway called STING, which helps the immune system sense danger. When that switch is stuck “on,” the body behaves as if there is an infection, even when there isn’t, driving ongoing inflammation in the skin, blood vessels, eyes, and sometimes the lungs. Naming the condition Sting-associated vasculopathy with onset in infancy helped tie the clinical picture to its biological cause.
Once considered rare, now recognized as part of a broader group of autoinflammatory diseases, the condition’s history reflects steady progress: careful bedside observation, improved imaging and biopsy techniques, and finally genetic confirmation. These historical steps also explain why some adults were only diagnosed after their child was found to have the condition—family stories made sense in hindsight.
Today, early symptoms of Sting-associated vasculopathy with onset in infancy can be spotted sooner, and treatments that target the overactive immune signals are becoming more widely used. Looking back helps explain how a puzzling infant rash and fever pattern became a well-defined diagnosis with a clearer path to care.